FDA Gives Go Ahead to Eli Lilly’s Alzheimer’s Diagnostic Amyvid

The FDA approved Eli Lilly’s radioactive diagnostic for detection of the tell-tale sign of Alzheimer’s disease, setting the stage for its pairing with experimental treatments for the condition now in late-stage development. Amyvid (florbetapir F 18 injection) binds to beta-amyloid plaques in patients’ brains. The plaques — detected using positron emission tomography, or PET scans — are believed to cause Alzheimer’s.
Washington Drug Letter